Nebivolol Actavis (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Actavis, is a beta‑blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. By selectively blocking β1‑adrenergic receptors and enhancing nitric‑oxide mediated vasodilation, it reduces heart rate and peripheral vascular resistance.

GNH USA supplies Nebivolol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers.

Nebivolol is a selective β1‑adrenergic antagonist used in the management of high‑blood‑pressure disorders.

- Hypertension: lowers systolic and diastolic blood pressure in adults. - Essential hypertension: provides long‑term control of chronic high blood pressure. - High blood pressure: reduces cardiovascular risk associated with sustained hypertension.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: especially upon standing. - Fatigue: general feeling of tiredness. - Nasal congestion: mild blockage of nasal passages. - Bradycardia: slower than normal heart rate. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction between heart chambers. - Symptomatic hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: narrowing of airways, particularly in patients with reactive airway disease. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before prescribing Nebivolol, clinicians should consider several safety factors.

- Cardiovascular assessment: evaluate heart rate and conduction system. - Respiratory conditions: use cautiously in asthma or COPD. - Renal impairment: dose may require adjustment in reduced kidney function. - Diabetes monitoring: beta‑blockers can mask hypoglycemia symptoms. - Drug interaction review: assess concomitant medications for additive bradycardia. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nebivolol can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Other β‑blockers: risk of excessive bradycardia. - Calcium channel blockers (verapamil, diltiazem): increased risk of atrioventricular block. - Potent CYP2D6 inhibitors (paroxetine, quinidine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Non‑selective β‑agonists: may diminish antihypertensive effect. - Diuretics: additive hypotensive effect, monitor blood pressure. - Insulin or oral hypoglycemics: potential masking of hypoglycemia symptoms.